Trial · NCT00521144
Adverse events360
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 360
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anorexia | Metabolism and nutrition disorders | Phase I; Level 1: Obatoclax Mesylate + Topotecan | 0 | 6 | 0 |
| other | Anorexia | Metabolism and nutrition disorders | Phase I; Level 2: Obatoclax Mesylate + Topotecan | 0 | 5 | 0 |
| other | Anorexia | Metabolism and nutrition disorders | Phase I; Level 3: Obatoclax Mesylate + Topotecan | 0 | 3 | 0 |
| other | Anorexia | Metabolism and nutrition disorders | Phase I; Level 4: Obatoclax Mesylate + Topotecan | 0 | 1 | 0 |
| other | Anorexia | Metabolism and nutrition disorders | Phase II Obatoclax Mesylate + Topotecan in SCLC | 2 | 7 | 2 |
| other | Ataxia (incoordination) | Nervous system disorders | Phase I; Level 1: Obatoclax Mesylate + Topotecan | 5 | 6 | 11 |
| other | Ataxia (incoordination) | Nervous system disorders | Phase I; Level 2: Obatoclax Mesylate + Topotecan | 2 | 5 | 6 |
| other | Ataxia (incoordination) | Nervous system disorders | Phase I; Level 3: Obatoclax Mesylate + Topotecan | 2 | 3 | 4 |
| other | Ataxia (incoordination) | Nervous system disorders | Phase I; Level 4: Obatoclax Mesylate + Topotecan | 0 | 1 | 0 |
| other | Ataxia (incoordination) | Nervous system disorders | Phase II Obatoclax Mesylate + Topotecan in SCLC | 7 | 7 | 21 |
| other | Constipation | Gastrointestinal disorders | Phase I; Level 1: Obatoclax Mesylate + Topotecan | 2 | 6 | 3 |
| other | Constipation | Gastrointestinal disorders | Phase I; Level 2: Obatoclax Mesylate + Topotecan | 1 | 5 | 1 |
| other | Constipation | Gastrointestinal disorders | Phase I; Level 3: Obatoclax Mesylate + Topotecan | 0 | 3 | 0 |
| other | Constipation | Gastrointestinal disorders | Phase I; Level 4: Obatoclax Mesylate + Topotecan | 0 | 1 | 0 |
| other | Constipation | Gastrointestinal disorders | Phase II Obatoclax Mesylate + Topotecan in SCLC | 2 | 7 | 3 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Phase I; Level 1: Obatoclax Mesylate + Topotecan | 0 | 6 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Phase I; Level 2: Obatoclax Mesylate + Topotecan | 0 | 5 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Phase I; Level 3: Obatoclax Mesylate + Topotecan | 0 | 3 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Phase I; Level 4: Obatoclax Mesylate + Topotecan | 0 | 1 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Phase II Obatoclax Mesylate + Topotecan in SCLC | 3 | 7 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00521144/events